Skip to content

Rheumatoid arthritis-associated interstitial lung disease

TL;DR — RA-ILD is one of RA’s most consequential complications and a major cause of premature death. Prevalence varies because cohorts use symptoms, pulmonary function tests, routine CT or systematic high-resolution CT; clinically apparent and subclinical disease must not be conflated (Kadura 2021, PMID 34168062; Sullivan 2024, PMID 39320427). Older age, male sex, smoking, high-titer RF/ACPA and the MUC5B promoter variant enrich risk, while usual interstitial pneumonia (UIP) pattern and physiologic progression worsen prognosis. HRCT defines pattern and extent; PFT trends quantify physiology. The 2023 ACR/CHEST framework conditionally supports mycophenolate, azathioprine or rituximab first line, and several immunomodulatory/antifibrotic options after progression, but RA-specific randomized evidence remains sparse (Saavedra 2025, PMID 39822854).

Phenotypes

Pattern/compartment Typical features Prognostic implication
UIP Basal/subpleural reticulation, traction bronchiectasis, honeycombing Generally worse than non-UIP patterns
NSIP Ground glass and fine reticulation; relative subpleural sparing possible Often more inflammatory/variable
Organizing pneumonia Patchy consolidation May be steroid-responsive; exclude infection
Airway disease Bronchiectasis, bronchiolitis Infection and symptom burden
Pleural disease Effusion, pleuritis Differential includes infection/heart failure
Drug pneumonitis Acute/subacute inflammatory injury Stop culprit and exclude infection

Lung involvement can precede, coincide with or follow articular RA, supporting heterogeneity in the lung–joint relationship (Kadura 2021, PMID 34168062; Kim 2023, PMID 37833957).

Risk factors

Factor Evidence direction Limitation
Older age Higher risk Confounded by smoking and cumulative disease
Male sex Higher ILD risk despite lower RA prevalence Referral and smoking differences
Smoking Higher risk Dose and timing measurement
High RF/ACPA Higher risk Correlated with smoking and disease phenotype
MUC5B promoter variant Strong UIP-enriched genetic association Ancestry and penetrance vary
High disease activity Associated with occurrence/progression Bidirectionality and treatment confounding
Subclinical CT abnormalities Predictive potential Many never progress clinically

No single factor is adequate as a screening test (Sullivan 2024, PMID 39320427; Kim 2023, PMID 37833957).

Identification and monitoring

Tool Role Limitation
Symptom history Dyspnea, dry cough, exercise tolerance Insensitive early; deconditioning overlaps
Examination Crackles, clubbing, oxygenation Normal exam does not exclude ILD
PFTs FVC, DLCO and longitudinal change Effort, anemia, emphysema and pulmonary vascular disease
HRCT Pattern, extent and alternate diagnosis Radiation and incidental/subclinical findings
Echocardiography Pulmonary pressure/cardiac differential Screening estimate, not definitive hemodynamics
Multidisciplinary review Integrates rheumatology, pulmonology, radiology Access and standardization

Routine HRCT for every person with RA remains debated. Risk-based screening is attractive but models require external validation; a 2025 retrospective model used 1,156 patients with external registry validation, not prospective outcome testing (Yao 2025, PMID 41299487).

Progressive pulmonary fibrosis is identified by worsening symptoms, physiology and/or imaging over time after excluding infection, heart failure, pulmonary embolism and drug toxicity. Absolute and relative FVC/DLCO changes must be interpreted with test quality and baseline values.

Treatment evidence

Therapy Evidence position Major uncertainty
Mycophenolate Conditional first-line option in guideline appraisal Mostly extrapolated/observational RA evidence
Azathioprine Conditional first-line option UIP safety/benefit uncertainty
Rituximab Conditional first-line/progression option Nonrandomized selection bias
Cyclophosphamide Option for severe/progressive disease Toxicity limits long-term use
Tocilizumab Conditional progression option Limited RA-ILD-specific evidence
Nintedanib Antifibrotic option in progressive phenotype Joint disease unaffected; subgroup evidence
Pirfenidone Conditional option after progression in RA-ILD Limited trial power
Long-term glucocorticoids Generally discouraged in fibrotic progression Infection and UIP concern

A systematic review/meta-analysis of rituximab studies found stabilization or improvement in many treated patients, but the underlying studies were observational and heterogeneous (Krishna Boppana 2024, PMID 38933731). Guideline recommendations are therefore conditional, not proof of equal choices (Saavedra 2025, PMID 39822854).

Methotrexate controversy

Acute methotrexate pneumonitis is a recognized uncommon hypersensitivity-like toxicity. Chronic fibrotic RA-ILD is different. Registry data from five Nordic countries found ILD incidence patterns in biologic initiators and examined methotrexate comedication, illustrating that confounding by RA severity and channeling complicate causal attribution (Provan 2024, PMID 39218450).

Automatically stopping effective methotrexate solely because stable RA-ILD exists may worsen joint control; continuing it during suspected acute pneumonitis is unsafe. The phenotype and time course determine the decision.

Prognosis and supportive care

UIP pattern, greater HRCT extent, lower FVC/DLCO and serial decline predict worse outcomes. Smoking cessation, vaccination, pulmonary rehabilitation, oxygen when indicated, reflux/OSA assessment, and early transplant discussion in appropriate progressive disease accompany pharmacotherapy.

Clinical-trial gaps

ClinicalTrials.gov searches on 2026-08-30 identified RA-ILD cohorts and interventional registrations including APRIL abatacept (NCT03084419), tofacitinib (NCT05246293), screening studies (NCT05855109; NCT03297775), and a connective-tissue-disease ILD trial (NCT06189495). Registry labels such as UNKNOWN mean the public record has not been updated, not that the intervention failed.

Quantitative risk, prognosis, and treatment anchors

Question Estimate Important caveat
How common? A 56-study meta-analysis including 11,851 RA-ILD cases estimated prevalence at 18.7% (95% CI 15.8–21.6; I²=96.4%) (Wang 2024, PMID 38547537). HRCT screening cohorts, symptomatic clinical cohorts, and claims definitions estimate different disease.
Who is at higher risk? Male sex OR 1.92 (95% CI 1.70–2.16), smoking OR 1.91 (1.48–2.47), ACPA positivity OR 2.11 (1.65–2.68), and moderate/high DAS28 OR 1.87 (1.36–2.58) (Wang 2024, PMID 38547537). Associations do not create a validated individual screening calculator.
What predicts death? UIP HR 1.88 (95% CI 1.14–3.10), emphysema HR 2.31 (1.58–3.39), acute exacerbation HR 2.70 (1.67–4.36), and male sex HR 1.44 (1.21–1.73) (Qiu 2021, PMID 34635095). Retrospective cohorts differ in treatment era and adjustment.
How should risk be screened? ACR/CHEST conditionally recommends PFTs and HRCT in at-risk systemic autoimmune disease and recommends against chest radiography, 6-minute-walk distance, bronchoscopy, or surgical biopsy as screening tests (Johnson 2024, PMID 38973714). Conditional guidance reflects low-certainty evidence and requires risk-based—not universal—implementation.
Does methotrexate cause chronic RA-ILD? International case-control data associated prior methotrexate with lower odds of RA-ILD (adjusted OR 0.43, 95% CI 0.26–0.69) and later detection (11.4 vs 4.0 years) (Juge 2021, PMID 32646919). Channeling away from methotrexate in lung-risk patients can create an artifactual protective association.
What does the larger drug literature show? Forty studies (486,465 patients; 3,928 incident ILD outcomes) found no RCT association for any specific DMARD; observational methotrexate OR was 0.49 (95% CI 0.32–0.76) (Zhang 2024, PMID 39413452). RCTs were not designed or powered for incident ILD; observational residual confounding remains.
Abatacept in established RA-ILD In a 57-patient prospective cohort, 71.9% improved or stabilized, 22.8% worsened, and 5.3% died over median 27.3 months (Mena-Vázquez 2022, PMID 35884786). No randomized comparator; indication and survivorship bias are substantial.
Antifibrotic treatment In 89 INBUILD participants with progressive RA-ILD, FVC decline was −82.6 versus −199.3 mL/year with placebo; difference 116.7 mL/year (95% CI 7.4–226.1). Diarrhea occurred in 61.9% versus 27.7% (Matteson 2023, PMID 37209188). Subgroup analysis supports progressive-fibrosis treatment, not all RA-ILD.

A separate risk-factor synthesis of 1,887 RA-ILD cases and 8,066 RA controls similarly found male sex OR 1.92, smoking OR 1.69, RF OR 1.72 and ACPA OR 1.58 (Zhang 2023, PMID 37352174). Concordance across meta-analyses increases confidence in direction, but not in a universal prevalence threshold. The principal controversy is therapeutic: articular control, inflammatory ILD and progressive fibrosis may require different agents, and evidence for most immunomodulators remains observational.

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Lee YH, et al. All-cause and cause-specific mortality in rheumatoid arthritis: a meta-analysis. Z Rheumatol. 2024. (PMID 38918258) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, extra-articular-and-comorbid-disease.md, overview.md
Restivo V, et al. Cardiovascular risk in rheumatological disease: systematic review and meta-analysis. Clin Rheumatol. 2022. (PMID 34454117) Adjacent evidence from extra-articular-and-comorbid-disease.md
Singh S, et al. Comparative cardiovascular risk with RA DMARDs. Ann Rheum Dis. 2020. (PMID 30875456) Adjacent evidence from extra-articular-and-comorbid-disease.md
Ytterberg SR, et al. Cardiovascular and cancer risk with tofacitinib. N Engl J Med. 2022. (PMID 35081280) Adjacent evidence from biologic-dmards.md, classification-and-diagnosis.md, conventional-dmards.md, epidemiology-and-burden.md, extra-articular-and-comorbid-disease.md, guidelines.md, jak-inhibitors-and-targeted-therapy.md, overview.md, red-flags-and-safety-concerns.md, treat-to-target-and-remission.md
Mehta B, et al. Serious infection risk in RA versus non-inflammatory musculoskeletal disease. Ann Rheum Dis. 2019. (PMID 31245055) Adjacent evidence from extra-articular-and-comorbid-disease.md
George MD, et al. Risk for serious infection with low-dose glucocorticoids in RA. Ann Intern Med. 2020. (PMID 32956604) Adjacent evidence from extra-articular-and-comorbid-disease.md, red-flags-and-safety-concerns.md
Xue AL, et al. Bone fracture risk in rheumatoid arthritis: meta-analysis. Medicine. 2017. (PMID 28885321) Adjacent evidence from extra-articular-and-comorbid-disease.md
Jin S, et al. Incidence of fractures in RA: systematic review and meta-analysis. Osteoporos Int. 2018. (PMID 29546507) Adjacent evidence from extra-articular-and-comorbid-disease.md
Kanis JA, et al. RA and subsequent fracture risk: individual-person meta-analysis to update FRAX. 2025. (PMID 39955689) Adjacent evidence from extra-articular-and-comorbid-disease.md
Turk MA, et al. Ocular manifestations in RA and connective-tissue disease: systematic review. J Rheumatol. 2021. (PMID 32358156) Adjacent evidence from extra-articular-and-comorbid-disease.md, red-flags-and-safety-concerns.md
Mertz P, et al. Rheumatoid vasculitis in 2023. Autoimmun Rev. 2023. (PMID 37468085) Adjacent evidence from extra-articular-and-comorbid-disease.md
de Cerqueira DPA, et al. Biological therapy in rheumatoid vasculitis: systematic review. Clin Rheumatol. 2021. (PMID 33058033) Adjacent evidence from extra-articular-and-comorbid-disease.md
Murray KE, et al. RA management before, during and after pregnancy. Rheumatol Adv Pract. 2019. (PMID 29748892) Adjacent evidence from extra-articular-and-comorbid-disease.md, red-flags-and-safety-concerns.md
Chin A, et al. DMARD recommendations in pregnancy and reproductive health: scoping review. 2025. (PMID 40256995) Adjacent evidence from extra-articular-and-comorbid-disease.md
Earwood JS, et al. Septic arthritis: diagnosis and treatment. Am Fam Physician. 2021. (PMID 34913662) Adjacent evidence from extra-articular-and-comorbid-disease.md, red-flags-and-safety-concerns.md
Margaretten ME, et al. Does this adult patient have septic arthritis? JAMA. 2007. (PMID 17405973) Adjacent evidence from extra-articular-and-comorbid-disease.md, red-flags-and-safety-concerns.md
Shlobin NA, et al. Cervical spine manifestations of rheumatoid arthritis: review. Neurosurg Rev. 2021. (PMID 33037539) Adjacent evidence from extra-articular-and-comorbid-disease.md, red-flags-and-safety-concerns.md
Joaquim AF, et al. Cervical spine involvement in RA: systematic review. Autoimmun Rev. 2014. (PMID 25151973) Adjacent evidence from extra-articular-and-comorbid-disease.md, red-flags-and-safety-concerns.md
Friedman MA, et al. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol. 2016. (PMID 26986246) Adjacent evidence from extra-articular-and-comorbid-disease.md, red-flags-and-safety-concerns.md
GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050. Lancet Rheumatol. 2023. (PMID 37795020) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, extra-articular-and-comorbid-disease.md, overview.md
Safiri S, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017. Ann Rheum Dis. 2019. (PMID 31511227) Adjacent evidence from epidemiology-and-burden.md, extra-articular-and-comorbid-disease.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • Which RA population benefits from systematic HRCT screening?
  • What constitutes a minimally important FVC/DLCO change in RA-ILD?
  • Which joint therapy best preserves lung outcomes in UIP versus inflammatory patterns?
  • When should antifibrotic therapy be combined with immunomodulation? (Saavedra 2025, PMID 39822854)
  • Can blood or airway biomarkers detect progression before physiologic decline?

References

  1. Kadura S, et al. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30:210011. PMID 34168062
  2. Sullivan DI, et al. Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): Update on Prevalence, Risk Factors, Pathogenesis, and Therapy. Curr Rheumatol Rep. 2024;26:431-449. PMID 39320427
  3. Saavedra AA, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline. Curr Treatm Opt Rheumatol. 2024;10:43-60. PMID 39822854
  4. Kim Y, et al. Etiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease. Int J Mol Sci. 2023;24:14509. PMID 37833957
  5. Yao C, et al. Rheumatoid arthritis-associated interstitial lung disease: clinical predictive model and external validation. Respir Res. 2025;26:331. PMID 41299487
  6. Krishna Boppana T, et al. Rituximab for rheumatoid arthritis-related interstitial lung disease: A systematic review and meta-analysis. Arch Rheumatol. 2024;39:317-329. PMID 38933731
  7. Provan SA, et al. Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic Registries. J Rheumatol. 2024;51:1111-1118. PMID 39218450
  8. Wang HF, et al. The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Ann Med. 2024;56:2332406. PMID 38547537
  9. Qiu M, et al. Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Respir Res. 2021;22:264. PMID 34635095
  10. Johnson SR, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024;76:1201-1213. PMID 38973714
  11. Juge PA, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57:2000337. PMID 32646919
  12. Zhang Q, et al. Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2024;69:152561. PMID 39413452
  13. Mena-Vázquez N, et al. Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease. Biomedicines. 2022;10:1480. PMID 35884786
  14. Matteson EL, et al. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial. Clin Rheumatol. 2023;42:2311-2319. PMID 37209188
  15. Zhang M, et al. Factors associated with interstitial lung disease in patients with rheumatoid arthritis: A systematic review and meta-analysis. PLoS One. 2023;18:e0286191. PMID 37352174
  16. Lee YH, et al. All-cause and cause-specific mortality in rheumatoid arthritis: a meta-analysis. Z Rheumatol. 2024;83:314-320. PMID 38918258
  17. Restivo V, et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev. 2022;21:102925. PMID 34454117
  18. Singh S, et al. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020;72:561-576. PMID 30875456
  19. Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316-326. PMID 35081280
  20. Mehta B, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5:e000935. PMID 31245055
  21. George MD, et al. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. Ann Intern Med. 2020;173:870-878. PMID 32956604
  22. Xue AL, et al. Bone fracture risk in patients with rheumatoid arthritis: A meta-analysis. Medicine (Baltimore). 2017;96:e6983. PMID 28885321
  23. Jin S, et al. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int. 2018;29:1263-1275. PMID 29546507
  24. Kanis JA, et al. Rheumatoid arthritis and subsequent fracture risk: an individual person meta-analysis to update FRAX. Osteoporos Int. 2025;36:653-671. PMID 39955689
  25. Turk MA, et al. Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. J Rheumatol. 2021;48:25-34. PMID 32358156
  26. Mertz P, et al. Rheumatoid vasculitis in 2023: Changes and challenges since the biologics era. Autoimmun Rev. 2023;22:103391. PMID 37468085
  27. de Cerqueira DPA, et al. Biological therapy in rheumatoid vasculitis: a systematic review. Clin Rheumatol. 2021;40:1717-1724. PMID 33058033
  28. Murray KE, et al. Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines. Ir J Med Sci. 2019;188:169-172. PMID 29748892
  29. Chin A, et al. Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review. Arthritis Care Res (Hoboken). 2025;77:1273-1281. PMID 40256995
  30. Earwood JS, et al. Septic Arthritis: Diagnosis and Treatment. Am Fam Physician. 2021;104:589-597. PMID 34913662
  31. Margaretten ME, et al. Does this adult patient have septic arthritis?. JAMA. 2007;297:1478-88. PMID 17405973
  32. Shlobin NA, et al. Cervical spine manifestations of rheumatoid arthritis: a review. Neurosurg Rev. 2021;44:1957-1965. PMID 33037539
  33. Joaquim AF, et al. Cervical spine involvement in rheumatoid arthritis--a systematic review. Autoimmun Rev. 2014;13:1195-202. PMID 25151973
  34. Friedman MA, et al. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol. 2016;28:330-6. PMID 26986246
  35. GBD 2021 Rheumatoid Arthritis Collaborators Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e594-e610. PMID 37795020
  36. Safiri S, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78:1463-1471. PMID 31511227